Inactief instrument

Andere talen Freeline Therapeutics Holdings plc

Aandelen

FRLN

US35655L2060

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Freeline Therapeutics Announces New Name and Brand	17/06
Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.	17/06
Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting	09/05
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	24/04
Syncona’s Takeover of Freeline Therapeutics Becomes Effective	20/02
Freeline Therapeutics Holdings plc Announces Resignation of Julia Gregory, Martin Andrews, Jeffrey Chodakewitz, Colin Love and Paul Schneider from the Board	20/02
Acquisition of Freeline by Syncona Becomes Effective	20/02
Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index	20/02
Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc.	20/02
Freeline shareholders approve Syncona acquisition	12/02
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona	12/02
Freeline Shareholders Approve Acquisition by Syncona	12/02
Syncona says Freeline trial for Gaucher disease treatment positive	19/01
European Equities Traded in the US as American Depositary Receipts Gain Friday	22/12
Pharma und Gesundheit: weitere Konsolidierung	13/12
Farmaceutica e salute: continua il consolidamento	11/12
Farmacia y salud: La consolidación continúa	11/12
Pharma & santé : poursuite de la consolidation	11/12
Hemophilia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics	08/12
Freeline Therapeutics : Reports Second Quarter 2023 Financial Results and Business Highlights - Form 6-K	01/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Freeline Therapeutics Holdings plc

Aandelen

FRLN

US35655L2060

Andere talen

Filters